铝碳酸镁片联合莫沙必利治疗胆汁反流性胃炎临床疗效观察

Clinical Efficacy of Hydrotalcite Combined with Mosapride in the Treatment of Patients with Bile Reflux Gastritis

目的:观察铝碳酸镁片联合莫沙必利对胆汁反流性胃炎临床治疗的效果。方法:选取2015年1月-2016年1月于天津市静海区医院收治的胆汁反流性胃炎患者40例,对照组给予莫沙必利片剂,每次5 mg,每日3次;观察组在对照组基础上加服铝碳酸镁片,每次500 mg,每日3次。药物治疗4周后观察两组患者临床症状、胃镜结果、总疗效及不良事件情况。结果:对照组治疗总有效率为60%;观察组治疗总有效率为90%,观察组与对照组总有效率相比差异具有统计学意义(P<0.05)。对照组不良事件发生率为15%,观察组不良事件发生率为10%,两组不良事件发生率相比无统计学差异(P>0.05)。结论:在莫沙比利应用基础上,铝碳酸镁片能明显增加治疗的有效性,并且不会明显增加不良事件的发生率。

Objective： To observe the clinical efficacy of Hydrotalcite combined with Mosapride in the treatment of patients with bile reflux gastritis. Methods： 40 patients with bile reflux gastritis in Jinghai District Hospital of Tianjin from January 2015 to January 2016 were selected and randomly divided into two groups, that is, control group and observation group. Patients were given Hydrotalcite （5mg, tid） in the control group, and patients were given Mosapride （500mg, tid） in addition to Hydrotalcite （5mg, tid） in the observation group. The clinical symptoms, gastroscope results, the overall efficacy and adverse events were analyzed after 4 weeks of drug treatment. Results： There was statistically significant difference in the total effective rate between the observation group （90%） and the control group （60%） （P〈 0.05）. But, there was not statistically significant difference in the adverse event rate between the observation group （10%） and the control group （15%）（P〉 0.05）. Conclusion： On the basis of Mosapride, Hydrotalcite could significantly increase the effectiveness of treatment without increasing the adverse event rate.